MARKET

APTO

APTO

Aptose Bioscienc
NASDAQ
0.5950
+0.0185
+3.21%
After Hours: 0.5950 0 0.00% 16:49 09/30 EDT
OPEN
0.5700
PREV CLOSE
0.5765
HIGH
0.5979
LOW
0.5700
VOLUME
148.55K
TURNOVER
0
52 WEEK HIGH
2.780
52 WEEK LOW
0.5421
MARKET CAP
54.92M
P/E (TTM)
-0.9326
1D
5D
1M
3M
1Y
5Y
Emergent (EBS) Acquires Worldwide Rights to Smallpox Antiviral
Emergent (EBS) completes the acquisition of worldwide rights to Tembexa, an FDA-approved smallpox oral antiviral for all ages, from Chimerix.
Zacks · 3d ago
Seagen's (SGEN) Tukysa Gets FDA Priority Review for New Indication
FDA grants priority review to Seagen's (SGEN) sNDA for Tukysa in combination with trastuzumab for previously treated HER2-positive metastatic colorectal cancer. A decision is due on Jan 19, 2023.
Zacks · 09/20 13:49
Aptose to Participate in Cantor Oncology, Hematology & HemeOnc Conference
SAN DIEGO and TORONTO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic...
GlobeNewswire · 09/14 11:30
Acadia's (ACAD) Rett Syndrome Drug NDA Gets FDA Priority Review
The FDA accepts and grants priority review to Acadia's (ACAD) NDA for trofinetide to treat Rett syndrome. A decision from the regulatory body is due on Mar 12, 2023.
Zacks · 09/13 12:44
Aptose Strengthens Board of Directors with Appointment of Bernd R. Seizinger, M.D., Ph.D.
New director brings big pharma oncology experience and biotech leadershipSAN DIEGO and TORONTO, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company dev...
GlobeNewswire · 09/13 11:30
BRIEF-Aptose's New “G3” Formulation Of Luxeptinib Boosts Bioavailability
BRIEF-Aptose's New “G3” Formulation Of Luxeptinib Boosts Bioavailability
Reuters · 09/12 12:11
Aptose Biosciences: Q2 Earnings Insights
Aptose Biosciences (NASDAQ:APTO) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:01 PM. Here's what investors need to know about the announcement.
Benzinga · 08/02 21:37
Aptose Biosciences Q2 EPS $(0.11) Beats $(0.13) Estimate
Aptose Biosciences (NASDAQ:APTO) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.13) by 15.38 percent. This is a 26.67 percent increase over losses of $(0.15) per share
Benzinga · 08/02 20:48
More
About APTO
Aptose Biosciences Inc. is a Canada-based clinical stage precision oncology biotechnology company. It is engaged in advancing kinase inhibitors to treat unmet medical needs in life-threatening cancers, such as acute myeloid leukemia (AML), certain B-cell malignancies, high-risk myelodysplastic syndrome (MDS) and other hematologic malignancies. Its HM43239 is being evaluated in an international Phase I/II study in patients with relapsed or refractory AML. Its Luxeptinib is being evaluated in a Phase I a/b trial in patients with relapsed or refractory B cell malignancies, and in a separate Phase I a/b trial in patients with relapsed or refractory AML or high-risk MDS. Its APTO-253 is a small molecule MYC oncogene inhibitor at the Phase Ia/b clinical trial stage of development for the treatment of patients with relapsed or refractory (R/R) blood cancers, including AML and high-risk MDS. Its APL-581 is a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program.

Webull offers kinds of Aptose Biosciences Inc stock information, including NASDAQ:APTO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APTO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading APTO stock methods without spending real money on the virtual paper trading platform.